| 00:00:00 | Formulation conditions antibody measurements |
| 00:00:17 | SEC – FDA Gold Standard |
| 00:00:38 | Protein Aggregation – Why The Concern? |
| 00:00:59 | The problem |
| 00:01:19 | Dynamic Light Scattering (DLS) |
| 00:01:38 | Batch vs. SEC Complementarity |
| 00:02:12 | SEC & DLS Pros & Cons |
| 00:02:35 | High Concentration – Issues To Consider |
| 00:03:13 | Effects, Symptoms, & Solutions |
| 00:03:29 | Antibody Formulations |
| 00:03:52 | IgG DLS Dilution Results* |
| 00:04:23 | DSL Size Distributions – Soup 1 |
| 00:04:51 | DLS Size Distributions – Soup 2 |
| 00:05:14 | DLS Size Distributions – Soup 3 |
| 00:05:26 | DLS Size Distributions – Soup 4 (PBS) |
| 00:05:43 | DLS Size At C = 0 |
| 00:06:05 | Oligomeric Distribution |
| 00:06:29 | Melting Point Comparison |
| 00:07:19 | Thank you! |
Aggregation in antibody formulations is of current concern because of the immunogenic response. This presentation gives examples of measurements of antibodies and their stability in various formulations at high concentration.